Stated Preferences in Non-Small-Cell Lung Cancer: A Discrete Choice Experiment

The study conducted a discrete choice experiment with 65 Brazilian patients with non-small-cell lung cancer to understand their treatment preferences, focusing on the trade-offs between treatment risks and benefits. It found that patients required a minimum survival gain of 11.72 months to accept severe tiredness and 19.72 months for severe skin rash, indicating that less than a year of survival gain was insufficient to justify severe side effects. The research highlighted the importance of considering patient preferences in treatment decisions and emphasized shared decision-making. However, the study's generalizability was limited due to its small sample size and convenience sampling method.